Pancreatic Cancer
Latest interviews and perspectives
Most recent
Video: Dr. Yoo-Joung Ko discusses results from the safety run in of a randomized phase II study of gemcitabine (gem) and nab-paclitaxel (nab-P) versus gem, nab-P, durvalumab, and tremelimumab as first-line therapy in mPDAC
Phase II LAPACT trial of nab-paclitaxel plus gemcitabine for patients with locally advanced pancreatic cancer
Hammel P, et al. ASCO GI 2018:204 Background About 30% of patients with pancreatic cancer have unresectable, locally advanced disease.1 Induction chemotherapy is recommended for these patients.2 Nanoparticle albumin-bound (nab)–paclitaxel plus gemcitabine treatment...
A retrospective study of nanoliposomal irinotecan with fluorouracil for the treatment of advanced pancreatic cancer
Glassman DC, et al. ASCO GI 2018:471 Background The phase III NAPOLI-1 trial demonstrated the efficacy of nanoliposomal irinotecan in combination with 5-fluorouracil and leucovorin (nal-IRI plus 5-FU/LV) in patients with advanced pancreatic adenocarcinoma (PDAC)...
Subgroup analysis by measurable metastatic lesion number and selected lesion locations at baseline in NAPOLI-1, a phase III study of nal-IRI ± 5-FU/LV in patients with mPDAC
Siveke JT, et al. ASCO GI 2018:460 Background Results from the phase III NAPOLI-1 trial demonstrated that addition of nanoliposomal irinotecan (nal-IRI) to 5-fluorouracil and leucovorin (5-FU/LV) significantly improved median overall survival (6.1 months vs. 4.2...
Subgroup analysis by baseline pain intensity and baseline analgesic use in NAPOLI-1, a study of nal-IRI ± 5-FU/LV in mPDAC patients previously treated with gemcitabine-based therapy
Mercadé TM, et al. ASCO GI 2018:379 Background The NAPOLI-1 study previously demonstrated that nanoliposomal irinotecan (nal-IRI) plus 5-fluorouracil and leucovorin (5-FU/LV) improved median overall survival (OS) by 45% and doubled median progression-free survival...
Other
Video: Dr. Alice Wei’s perspective on the NIFE trial at ESMO 2017
Video: Dr. Christine Brezden-Masley’s perspective on the NIFE trial at ESMO 2017
Video: Dr. Winson Cheung compares different schedules of nab-paclitaxel with gemcitabine in mPDAC treatment
Video: Dr. Winson Cheung discusses “Subgroup analysis by prior lines of metastatic therapy in NAPOLI-1″
Video: Dr. Sharlene Gill discusses adding napabucasin to gemcitabine/nab-paclitaxel therapy in mPDAC
Video: Dr. Sharlene Gill discusses subgroup analyses by prior lines of metastatic therapy in NAPOLI-1
Subgroup analysis by prior lines of metastatic therapy in NAPOLI-1: A phase III study of nal-IRI ± 5-FU/LV versus 5-FU/LV in metastatic pancreatic cancer previously treated with gemcitabine-based therapy
Macarulla T, et al. ASCO 2017:4127 Background Liposomal irinotecan (nal-IRI) is a novel liposomal formulation of the topoisomerase I inhibitor irinotecan. nal-IRI has been approved in the U.S. for use in combination with 5-fluorouracil and leucovorin (5-FU/LV) in...
An Interview with Dr. Barbara Melosky on the Canadian Treatment Landscape for Pancreatic Cancer
After the ESMO 2016 Annual Meeting, New Evidence spoke with Dr. Barbara Melosky, Medical Oncologist at the BC Cancer Agency, about the latest data and current treatment landscape in pancreatic cancer. New Evidence: What is your course of action with patients who have...
Dr. Sandy Sehdev shares his perspectives on nal-IRI and NAPOLI-1 at the ESMO 2016 Congress
https://youtu.be/u2CGW3iz2Ac Watch more videos Videos Papers Slides Best Practice...
Dr. Mark Vincent shares his perspectives on nal-IRI and NAPOLI-1 at the ESMO 2016 Congress
https://youtu.be/8yUG27WftTs Watch more videos Videos Papers Slides Best Practice...
Twitter feed